



## Model List of Essential Medicines



### **Azithromycin** [General information](#)

Section

Watch group antibiotics

- Oral > Liquid: 200 mg per 5 mL (anhydrous) powder for oral liquid
- Oral > Solid > dosage form: 250 mg (anhydrous); 500 mg (anhydrous)

Indications

**First choice**

[Trachoma](#) [Cholera](#) [Cholera \[children\]](#) [Paratyphoid fever](#) [Chlamydia trachomatis](#) [Typhoid fever](#) [Yaws](#) co-prescribed with [ceftriaxone](#) [Gonococcal infection](#)

**Second choice**

[Infectious gastroenteritis or colitis without specification of infectious agent](#) co-prescribed with [cefixime](#) [Gonococcal infection](#)



### **Cefepime** [General information](#)

Section

Watch group antibiotics

- Parenteral > General injections > unspecified: 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection; 2 g in vial (as hydrochloride) powder for injection

Indications

[Other specified bacterial diseases](#)



### **Cefixime** [General information](#)

Section

Watch group antibiotics

- Oral > Liquid: 100 mg per 5 mL powder for oral liquid
- Oral > Solid: 200 mg (as trihydrate); 400 mg (as trihydrate)

Indications

**Second choice**

[Infectious gastroenteritis or colitis without specification of infectious agent](#) [Gonococcal infection](#)



### **Cefotaxime** [General information](#)

Section

Watch group antibiotics

- Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt)
- Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)

Indications

**First choice**

[Bacterial meningitis](#) [Inflammatory and other diseases of prostate \(severe\)](#) [Acute pyelonephritis \(severe\)](#) [Bacterial pneumonia \(Community-acquired pneumonia - severe\) \[children\]](#) [Bacterial pneumonia \(Community-acquired pneumonia - severe\)](#) [Peritoneal abscess \(mild-moderate\)](#) [Peritoneal abscess \(severe\)](#) [Other specified pneumonia \(Hospital-acquired pneumonia\)](#) [Peritonitis \(mild-moderate\)](#) [Peritonitis \(severe\)](#)

**Second choice**

[Inflammatory and other diseases of prostate \(mild to moderate\)](#) [Acute pyelonephritis \(mild to moderate\)](#) [Sepsis without septic shock](#) [Bacterial infection of joint](#) [Osteomyelitis or osteitis](#)

Other indications

[Bacterial infection of unspecified site](#)

**Ceftazidime** [General information](#)

Section

Watch group antibiotics

- Parenteral > General injections > unspecified: 250 mg in vial (as pentahydrate) powder for injection; 1 g in vial (as pentahydrate) powder for injection

Indications

**First choice**

[Endophthalmitis](#)

Other indications

[Pseudomonas aeruginosa resistant to other antibiotic](#)

**Ceftriaxone** [General information](#)

Section

Watch group antibiotics

- Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)
- Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)
- Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)
- Parenteral > Locoregional injections > Intravitreal: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)
- Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)

Indications

**First choice**

[Other specified pneumonia \(Hospital-acquired pneumonia\)](#) [Inflammatory and other diseases of prostate \(severe\)](#) [Bacterial meningitis](#) [Acute pyelonephritis \(severe\)](#) [Paratyphoid fever](#) [Gonococcal infection](#) [Typhoid fever](#) [Peritonitis \(mild-moderate\)](#) [Peritonitis \(severe\)](#) [Peritoneal abscess \(mild-moderate\)](#) [Peritoneal abscess \(severe\)](#) [Endophthalmitis](#) [Bacterial pneumonia \(Community-acquired pneumonia - severe\)](#) [Bacterial pneumonia \(Community-acquired pneumonia - severe\) \[children\]](#) co-prescribed with [metronidazole](#) [Necrotising fasciitis](#)

**Second choice**

[Inflammatory and other diseases of prostate \(mild to moderate\)](#) [Acute pyelonephritis \(mild to moderate\)](#) [Bacterial infection of joint](#) [Sepsis without septic shock](#) [Osteomyelitis or osteitis](#) [Infectious gastroenteritis or colitis without specification of infectious agent](#)

Other indications

[Bacterial infection of unspecified site](#)

**Cefuroxime** [General information](#)

Section

Watch group antibiotics

- Parenteral > General injections > IV: 250 mg in vial (as sodium salt) powder for injection; 750 mg in vial (as sodium salt) powder for injection; 1.5 g in vial (as sodium salt) powder for injection

Indications

Second choice

[Other specified prophylactic measures](#)

**Ciprofloxacin** [General information](#)

Section

Watch group antibiotics

- Parenteral > General injections > IV: 2 mg per mL (as hyclate)
- Oral > Liquid: 250 mg per 5 mL (anhydrous)
- Oral > Solid: 250 mg (as hydrochloride)
- Oral > Solid > dosage form: 250 mg (as hydrochloride); 500 mg (as hydrochloride); 100 mg (as hydrochloride)
- Oral > Solid > dosage form: 250 mg (as hydrochloride); 500 mg (as hydrochloride)

Indications

First choice

[Acute pyelonephritis \(mild to moderate\)](#) [Infectious gastroenteritis or colitis without specification of infectious agent](#) [Paratyphoid fever](#) [Typhoid fever](#) [Neutropenia \(low-risk\)](#) [Inflammatory and other diseases of prostate \(mild to moderate\)](#)

Second choice

[Cholera](#) [Cholera \[children\]](#) [Peritonitis \(mild-moderate\)](#) [Peritoneal abscess \(mild-moderate\)](#)

Other indications

[Bacterial infection of unspecified site](#)

**Clarithromycin** [General information](#)

Section

Watch group antibiotics

- Oral > Liquid: 125 mg per 5 mL powder for oral liquid; 250 mg per 5 mL powder for oral liquid
- Parenteral > General injections > unspecified: 500 mg in vial powder for injection
- Oral > Solid > dosage form: 500 mg; 250 mg
- Oral > Solid > dosage form: 500 mg

Indications

First choice

co-prescribed with [cefotaxime](#) [Bacterial pneumonia \(Community-acquired pneumonia - severe\)](#) co-prescribed with [ceftriaxone](#) [Bacterial pneumonia \(Community-acquired pneumonia - severe\)](#)

Second choice

[Acute pharyngitis](#) co-prescribed with [amoxicillin + clavulanic acid](#) [Bacterial pneumonia \(Community-acquired pneumonia - severe\)](#)

Other indications

[Helicobacter pylori associated gastric ulcer](#)

**Delafloxacin** [General information](#)

Section

Watch group antibiotics

- Parenteral > General injections > IV: 300 mg lyophilized powder for injection
- Oral > Solid: 450 mg

Indications

[Methicillin resistant Staphylococcus aureus](#)

**Erythromycin** [General information](#)

Section

Watch group antibiotics

- Parenteral > General injections > IV: 500 mg in vial powder for injection (as lactobionate)
- Oral > Liquid: 125 mg per 5 mL (as stearate or ethylsuccinate)
- Oral > Solid: 250 mg (as stearate or ethylsuccinate)

Indications

**Second choice**

Therapeutic equivalent to [clarithromycin](#) for [Acute pharyngitis](#)

Other indications

[Bacterial infection of unspecified site](#)

**Flomoxef [General information](#)**

Section

Watch group antibiotics

- Parenteral > General injections > IV: 0.5 g in vial powder for injection; 1 g in vial powder for injection

Indications

[Other specified other antibiotic resistant Enterobacterales](#)

**Fourth generation cephalosporins [General information](#)**

Section

Watch group antibiotics

- .

Indications

[Other specified bacterial diseases](#)

**Imipenem + cilastatin [General information](#)**

Section

Watch group antibiotics

- Parenteral > General injections > IV: 250 mg (as monohydrate) + 250 mg (as sodium salt) powder for injection; 500 mg (as monohydrate) + 500 mg (as sodium salt) powder for injection

Indications

**Second choice**

Therapeutic equivalent to [meropenem](#) for [Peritonitis \(severe\)](#) Therapeutic equivalent to [meropenem](#) for [Peritoneal abscess \(severe\)](#) Therapeutic equivalent to [meropenem](#) for [Neutropenia \(high-risk\)](#)

Other indications

[Pseudomonas aeruginosa resistant to other antibiotic](#) [Antibiotic resistant Acinetobacter baumannii](#)

**Meropenem [General information](#)**

Section

Watch group antibiotics

- Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection

Indications

**Second choice**

[Neonatal meningitis](#) [Peritonitis \(severe\)](#) [Peritoneal abscess \(severe\)](#) [Neutropenia \(high-risk\)](#)

**Piperacillin + tazobactam [General information](#)**

Section

Watch group antibiotics

- Parenteral > General injections > IV: 2 g (as sodium salt) + 250 mg (as sodium salt) powder for injection; 4 g (as sodium salt) + 500 mg (as sodium salt) powder for injection

Indications

**First choice**

[Neutropenia \(high-risk\)](#) [Other specified pneumonia \(Hospital-acquired pneumonia\)](#) [Peritonitis \(severe\)](#) [Peritoneal](#)

[abscess \(severe\)](#) co-prescribed with [clindamycin](#) [Necrotising fasciitis](#)



### **Vancomycin** [General information](#)

#### Section

#### Watch group antibiotics

- Parenteral > General injections > IV: 250 mg in vial (as hydrochloride) powder for injection
- Oral > Solid > capsule: 125 mg (as hydrochloride); 250 mg (as hydrochloride)
- Parenteral > General injections > IV: 250 mg in vial (as hydrochloride) powder for injection; 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection
- Parenteral > Locoregional injections > Intravitreal: 250 mg in vial (as hydrochloride) powder for injection; 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection

#### Indications

#### **First choice**

[Necrotising fasciitis](#) co-prescribed with [ceftazidime](#) [Endophthalmitis](#) co-prescribed with [ceftriaxone](#)  
[Endophthalmitis](#)

#### **Second choice**

[Intestinal infections due to Clostridioides difficile](#) [Neutropenia \(high-risk\)](#)

#### Other indications

[Methicillin resistant Staphylococcus aureus](#)